Bydureon receives positive CHMP opinion for BCise
29 June 2018 15:00 BST Bydureon receives positive EU CHMP opinion for new BCise device for patients with type-2 diabetes New formulation of once-weekly Bydureon in a pre-filled device recommended to help improve glycaemic control AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending inclusion of Bydureon (2mg prolonged-release suspension for injection) BCise device as a new formulation within the marketing authorisation for Bydureon (exenatide extended-release)